WHO ICTRP trial
A single-arm, open, phase II exploratory clinical study of Envafolimab combined…
ChiCTR2300069478 · Chinese Clinical Trial Registry (ChiCTR) · Not Recruiting
Key facts
| Trial ID | ChiCTR2300069478 |
|---|---|
| Public title | A single-arm, open, phase II exploratory clinical study of Envafolimab combined with Lenvatinib for neoadjuvant treatment of potentially operable liver cancer |
| Scientific title | A single-arm, open, phase II exploratory clinical study of Envafolimab combined with Lenvatinib for neoadjuvant treatment of potentially operable liver cancer |
| Primary sponsor | Shandong Provincial Hospital |
| Registry | Chinese Clinical Trial Registry (ChiCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional study |
| Phase | 2 |
| Countries | China |
| Conditions | Liver cancer |
| Interventions | Group of liver cancer:Envafolimab combined with Lenvatinib |
| Registration date | Mar 17, 2023 |
| Target size | Group of liver cancer:30 |
| Registry page | chictr.org.cn |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: